References

1. Ettinger C, Karnell J, Damschroder M, Chowdhury P, Xiao X, Tsui P, Varkey R, Drabic S, Carter L, Herbst R et al.. (2018) Antibodies specific for IL-21 and uses thereof. Patent number: US10022443B2. Assignee: Boston Pharmaceuticals Inc. Priority date: 08/04/2014. Publication date: 17/07/2018.

2. Joalland N, Chauvin C, Oliver L, Vallette FM, Pecqueur C, Jarry U, Scotet E. (2018) IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors. J Immunother, 41 (5): 224-231. [PMID:29683891]

3. Lamprecht B, Kreher S, Anagnostopoulos I, Jöhrens K, Monteleone G, Jundt F, Stein H, Janz M, Dörken B, Mathas S. (2008) Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood, 112 (8): 3339-47. [PMID:18684866]

4. Wei L, Laurence A, Elias KM, O'Shea JJ. (2007) IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem, 282 (48): 34605-10. [PMID:17884812]

5. Wurster AL, Rodgers VL, Satoskar AR, Whitters MJ, Young DA, Collins M, Grusby MJ. (2002) Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med, 196 (7): 969-77. [PMID:12370258]